{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T22:36:13Z","timestamp":1769207773315,"version":"3.49.0"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2,15]]},"DOI":"10.2146\/ajhp160006","type":"journal-article","created":{"date-parts":[[2017,2,8]],"date-time":"2017-02-08T11:40:25Z","timestamp":1486554025000},"page":"201-208","source":"Crossref","is-referenced-by-count":20,"title":["Ceftaroline for the treatment of methicillin-resistant<i>Staphylococcus aureus<\/i>bacteremia"],"prefix":"10.1093","volume":"74","author":[{"given":"Bryan Pinckney","family":"White","sequence":"first","affiliation":[{"name":"OU Medical Center, Oklahoma City, OK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie E.","family":"Barber","sequence":"additional","affiliation":[{"name":"University of Mississippi School of Pharmacy, Jackson, MS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayla R.","family":"Stover","sequence":"additional","affiliation":[{"name":"University of Mississippi School of Pharmacy, Jackson, MS"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041103130951500_b1-0740201","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/587673","article-title":"The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitals","volume":"46","author":"Kaye","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103130951500_b2-0740201","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5694\/j.1326-5377.2009.tb02841.x","article-title":"Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand","volume":"191","author":"Turnidge","year":"2009","journal-title":"Med J Aust"},{"key":"key\n\t\t\t\t2019041103130951500_b3-0740201","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/cid\/cit112","article-title":"Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg\/L: a matched cohort study","volume":"56","author":"Murray","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103130951500_b4-0740201","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health-Syst Pharm"},{"key":"key\n\t\t\t\t2019041103130951500_b5-0740201","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.1128\/AAC.00168-11","article-title":"Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial","volume":"55","author":"Bosso","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103130951500_b6-0740201","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103130951500_b7-0740201","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103130951500_b8-0740201","unstructured":"Forest Pharmaceuticals. Teflaro (ceftaroline fosamil) prescribing information. http:\/\/pi.actavis.com\/data_stream.asp?product_group=1915&p=pi&language=E (accessed 2015 Jun 13)."},{"issue":"suppl 3","key":"key\n\t\t\t\t2019041103130951500_b9-0740201","first-page":"S19","article-title":"Focus 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"suppl 3","key":"key\n\t\t\t\t2019041103130951500_b10-0740201","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1093\/jac\/dkr097","article-title":"Focus 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"suppl 4","key":"key\n\t\t\t\t2019041103130951500_b11-0740201","first-page":"iv41","article-title":"CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corey","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"suppl 4","key":"key\n\t\t\t\t2019041103130951500_b12-0740201","first-page":"iv53","article-title":"CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Wilcox","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041103130951500_b13-0740201","unstructured":"Brooks M . FDA OKs label update for antibiotic ceftaroline fosamil. www.medscape.com\/viewarticle\/850463v (accessed 2015 Nov 4)."},{"key":"key\n\t\t\t\t2019041103130951500_b14-0740201","unstructured":"ClinicalTrials.gov. Safety and efficacy study of ceftaroline in subjects with Staphylococcus aureus bacteremia or with persistent methicillin-resistant Staphylococcus aureus bacteremia. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01701219?term=ceftaroline+bacteremia&rank=11 (accessed 2015 May 19)."},{"key":"key\n\t\t\t\t2019041103130951500_b15-0740201","article-title":"Interim analysis of ceftaroline fosamil for the treatment of Staphylococcus aureus bacteremia","author":"Fowler"},{"key":"key\n\t\t\t\t2019041103130951500_b16-0740201","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1086\/514622","article-title":"The pharmacodynamics of beta-lactams","volume":"27","author":"Turnidge","year":"1998","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103130951500_b17-0740201","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1128\/AAC.02371-13","article-title":"Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy","volume":"58","author":"Casapao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103130951500_b18-0740201","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofu046","article-title":"Ceftaroline in combination with trimethoprim-sulfamethoxazole for salvage therapy of methicillin-resistant Staphylococcus aureus bacteremia and endocarditis","volume":"1","author":"Fabre","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"key\n\t\t\t\t2019041103130951500_b19-0740201","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/phar.1435","article-title":"High incidence of discontinuations due to adverse events in patients treated with ceftaroline","volume":"34","author":"Jain","year":"2014","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t2019041103130951500_b20-0740201","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/phar.1596","article-title":"Agranulocytosis with ceftaroline high-dose monotherapy or combination therapy with clindamycin","volume":"35","author":"Varada","year":"2015","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t2019041103130951500_b21-0740201","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/AAC.01471-15","article-title":"Neutropenia associated with long-term ceftaroline use","volume":"60","author":"LaVie","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103130951500_b22-0740201","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1128\/AAC.04614-14","article-title":"Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program","volume":"59","author":"Sader","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103130951500_b23-0740201","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1128\/AAC.00484-13","article-title":"Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011","volume":"57","author":"Sader","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103130951500_b24-0740201","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1128\/AAC.00636-09","article-title":"In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model","volume":"53","author":"Vidaillac","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103130951500_b25-0740201","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/cid\/cis492","article-title":"In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates","volume":"55","author":"Saravolatz","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103130951500_b26-0740201","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1128\/AAC.01586-12","article-title":"Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic\/pharmacodynamic model","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103130951500_b27-0740201","doi-asserted-by":"crossref","first-page":"9451","DOI":"10.1073\/pnas.0609839104","article-title":"Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing","volume":"104","author":"Mwangi","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t2019041103130951500_b28-0740201","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40121-014-0023-0","article-title":"Observation of \u201cseesaw effect\u201d with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains","volume":"3","author":"Barber","year":"2014","journal-title":"Infect Dis Ther"},{"key":"key\n\t\t\t\t2019041103130951500_b29-0740201","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041103130951500_b30-0740201","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1128\/AAC.00386-15","article-title":"Evaluation of ceftaroline alone and in combination against biofilm-producing methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin and vancomycin in an in vitro pharmacokinetic\/pharmacodynamic model","volume":"59","author":"Barber","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103130951500_b31-0740201","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1128\/AAC.34.12.2312","article-title":"Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus","volume":"34","author":"Lucet","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103130951500_b32-0740201","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1128\/AAC.02764-13","article-title":"A novel approach utilizing biofilm time-kill curves to assess the bactericidal activity of ceftaroline combinations against biofilm-producing methicillin-resistant Staphylococcus aureus","volume":"58","author":"Barber","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103130951500_b33-0740201","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1128\/AAC.01242-06","article-title":"In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model","volume":"51","author":"Jacqueline","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103130951500_b34-0740201","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/AAC.01516-13","article-title":"In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure","volume":"58","author":"Bhalodi","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103130951500_b35-0740201","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1128\/AAC.02354-12","article-title":"Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103130951500_b36-0740201","first-page":"2015","article-title":"Mycotic pseudoaneurysm by vancomycin-intermediate Staphylococcus aureus: a rare cause of persistent bacteraemia","volume":"1","author":"Mahfood Haddad","year":"2015","journal-title":"BMJ Case Rep"},{"key":"key\n\t\t\t\t2019041103130951500_b37-0740201","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1128\/AAC.00797-12","article-title":"Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity","volume":"56","author":"Rose","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103130951500_b38-0740201","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s15010-015-0763-0","article-title":"Daptomycin non-susceptible, vancomycin-intermediate Staphylococcus aureus endocarditis treated with ceftaroline and daptomycin: case report and brief review of the literature","volume":"43","author":"Baxi","year":"2015","journal-title":"Infection"},{"key":"key\n\t\t\t\t2019041103130951500_b39-0740201","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/jac\/dku322","article-title":"Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia","volume":"70","author":"Barber","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041103130951500_b40-0740201","unstructured":"Unger NR Osiyemi OO Richardson RM . Ceftaroline and gentamicin for the treatment of daptomycin-non-susceptible methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis in a pregnant patient. www.microbiologyresearch.org\/docserver\/fulltext\/jmmcr\/1\/2\/jmmcr002394.pdf?expires=1479308544&id=id&accname=guest&checksum=6CCCC27F4B539C706405BA575BB78481 (accessed 2016 Nov 16)."},{"key":"key\n\t\t\t\t2019041103130951500_b41-0740201","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10156-012-0449-9","article-title":"The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients","volume":"19","author":"Lin","year":"2013","journal-title":"J Infect Chemother"},{"key":"key\n\t\t\t\t2019041103130951500_b42-0740201","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/jac\/dks006","article-title":"Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy","volume":"67","author":"Ho","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041103130951500_b43-0740201","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/jac\/dku085","article-title":"Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study","volume":"69","author":"Tattevin","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041103130951500_b44-0740201","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijantimicag.2014.07.024","article-title":"Use of ceftaroline after glycopeptide failure to eradicate methicillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations","volume":"44","author":"Paladino","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019041103130951500_b45-0740201","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t2019041103130951500_b46-0740201","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103130951500_b47-0740201","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ijantimicag.2013.07.005","article-title":"Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature","volume":"42","author":"Polenakovik","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019041103130951500_b48-0740201","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/IPC.0000000000000191","article-title":"Ceftaroline fosamil for the treatment of Staphylococcus aureus bacteremia secondary to acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia","volume":"23","author":"Vazquez","year":"2015","journal-title":"Infect Dis Clin Pract"},{"key":"key\n\t\t\t\t2019041103130951500_b49-0740201","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/431979","article-title":"Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database","volume":"41","author":"Miro","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103130951500_b50-0740201","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1086\/496923","article-title":"Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia?","volume":"41","author":"Zahar","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103130951500_b51-0740201","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/655827","article-title":"Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection","volume":"51","author":"Corey","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041103130951500_b52-0740201","article-title":"A single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics (PK) of ceftaroline (CPT) administered by intramuscular (im) injection to healthy subjects","author":"Thye"},{"key":"key\n\t\t\t\t2019041103130951500_b53-0740201","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1128\/AAC.48.12.4665-4672.2004","article-title":"Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model","volume":"48","author":"LaPlante","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041103130951500_b54-0740201","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t2019041103130951500_b55-0740201","article-title":"Single-dose pharmacokinetics (PK) of ceftaroline (PPI-0903) in healthy subjects","author":"Ge"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/74\/4\/201\/28336933\/ajhp0201.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T03:00:51Z","timestamp":1601607651000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/74\/4\/201\/5103343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,15]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,2,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp160006","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,2,15]]},"published":{"date-parts":[[2017,2,15]]}}}